TABLE 2.

Clinical and Epidemiological data of the five patients with severe COVID‐19 that developed Trichosporon asahii fungemia

Condition	Patient Data
Age	57	74	75	73	72
Sex	Male	Male	Female	Male	Male
Body Mass Index ≥35	No	No	Yes	Yes	Yes
Diabetes mellitus	Yes	No	No	Yes	No
ICU length of stay before fungemia (days) a	30	31	27	15	11
Mechanical ventilation duration before fungemia (days)	30	27	27	15	11
Renal replacement therapy duration before fungemia (days)	0	16	9	11	11
Broad‐spectrum antibiotic therapy duration with anti‐anaerobe activity before Trichosporon fungemia (days)	30	30	26	15	10
Diarrhoea duration before Trichosporon fungemia (days)	16	12	4	0	0
Corticosteroid therapy duration before fungemia (days)	30	30	26	15	10
Corticosteroid exposure during fungemia	Yes	Yes	Yes	Yes	Yes
Enteroccus spp. bacteremia before or at Trichosporon fungemia	No	Yes	No	No	Yes
Candidemia before Trichosporon fungemia	Yes	Yes	Yes	No	No
Echinocandin exposure before Trichosporon fungemia (days)	13	9	6	9	5
Echinocandin breakthrough infection	No	Yes	No	Yes	Yes
CVC at fungemia b	Yes	Yes	Yes	Yes	Yes
Pitt bacteremia score at fungemia	7	14	10	10	14
Blood neutrophils count at fungemia (cells/mm3)	7200	2750	18,200	1260	970
Blood Lymphocyte count at fungemia (cells/mm3)	1440	300	1500	950	550
Voriconazole therapy	Yes	No	Yes	Yes	Yes
CVC removal after Trichosporon fungemia	Yes	No	Yes	Yes	Yes
7‐day outcome	Alive	Dead	Alive	Alive	Alive
14‐day outcome	Alive	Dead	Alive	Dead	Dead
30‐day outcome	Alive	Dead	Dead	Dead	Dead

^a ICU, Intensive care unit.

^b CVC, central venous catheter.